In the TCGA-AML cohort, high expression of IGF2BP3 was associated with shorter overall survival times in patients with AML (HR = 2.578, 95% CI = 1.444–4.602, P = 0.001), and high expression of HNRNPA2B1 was associated with longer overall survival times in patients with AML (HR = 0.991, 95% CI = 0.982–0.999, P = 0.027). This evidence concerns the gene IGF2BP3 and acute myeloid leukemia.